AmVac and Taiwan National Health Research Institute Cooperate to Develop Nasal Spray Avian Flu Vaccine
AmVac AG (Zug, Switzerland) has formed a collaboration with the National Health Research Institutes in Taiwan to develop a nasal spray vaccine against the H5N1 avian influenza.
AmVac AG (Zug, Switzerland) has formed a collaboration with the National Health Research Institutes in Taiwan to develop a nasal spray vaccine against the H5N1 avian influenza.
The vaccine will use AmVac’s adjuvant, MALP-2, which is suitable for absorption through mucosal membranes.
Up to now, the development of a flu vaccine spray has been hampered by the lack of a safe adjuvant capable of enhancing strong mucosal immunity. AmVac has acquired exclusive rights to the adjuvant MALP-2 (Macrophage Activating Lipopeptide-2), developed by C. Guzman at the Helmholtz Center for Infection Research in Braunschweig, for all infectious diseases worldwide. This synthetic, well-tolerated class of adjuvants acts as a toll-like receptor agonist in activating cells of the immune system and thus at central sites in mediation of the immune response. Preliminary results in mice have revealed that the pandemic H5N1 flu vaccine combined with MALP-2 elicits flu-specific antibodies following intranasal immunization.
The Future of Cleanroom Construction: How Hybrid Solutions are Changing the Game
May 14th 2025Imagine a world where cleanroom facilities—essential for pharmaceutical manufacturing, biotechnology, and high-tech industries—are built with unparalleled speed, precision, and efficiency. That world is here, thanks to the hybrid construction approach. By blending traditional stick-built methods with modular and prefabricated solutions, companies are overcoming the limitations of conventional construction while ensuring compliance with stringent industry regulations. In this interview, we explore how hybrid cleanroom construction is transforming the industry, offering faster project timelines, improved quality control, and significant cost advantages. Join us as we delve into this game-changing approach with industry experts who are leading the charge in revolutionizing cleanroom infrastructure.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
